Merck to slash more than 100 R&D jobs from French site

Merck is shuttering an R&D site in Riom in the heart of France. (Merck)

While Merck announced it was spending a few hundred million on an early-stage biotech this morning, we have now learned that it is also shuttering an R&D site in Riom in the heart of France.

The U.S. Big Pharma is shutting down the research and manufacturing site, which has seen its use lessen over the years. It has a focus on antibiotics, anti-inflammatory and vaccine work.   

“The number of toxicology studies entrusted to the research center has considerably decreased in recent years,” according to a report by French newspaper La Montagne and later confirmed to FierceBiotech, “whose volume no longer makes it possible to ensure optimal use of the center’s capacity.”

Virtual Roundtable

ASCO Explained: Expert predictions and takeaways from the world's biggest cancer meeting

Join FiercePharma for our ASCO pre- and post-show webinar series. We'll bring together a panel of experts to preview what to watch for at ASCO. Cancer experts will highlight closely watched data sets to be unveiled at the virtual meeting--and discuss how they could change prescribing patterns. Following the meeting, we’ll do a post-show wrap up to break down the biggest data that came out over the weekend, as well as the implications they could have for prescribers, patients and drugmakers.

The research center currently has 106 employees who will be let go, with another 100 going from its manufacturing side. Merck added that it may look to sell the site off.


Suggested Articles

The FDA named more than two dozen coronavirus antibody tests that should be taken off the market weeks after the agency clamped down on tests.

Inovio CEO J. Joseph Kim is undeterred by short sellers and other detractors who doubt his company can shuttle a COVID-19 DNA vaccine to market.

The machine-learning programs scroll through data to detect hard-to-spot patterns. Yet few have been tested against standard procedures.